On December 20, 2017, the U.S. Food and Drug Administration (FDA) granted a supplemental approval for Opdivo (nivolumab). This approval, designated BLA 125554 S-55, specifically pertains to an expansion of the drug's efficacy profile, allowing for new therapeutic applications.
Background
Nivolumab, marketed as Opdivo, is an immunotherapy drug that functions as a programmed death-1 (PD-1) blocking antibody. It works by enhancing the body's immune system to recognize and combat cancer cells. As a key checkpoint inhibitor, nivolumab has been a significant therapeutic advancement in oncology, utilized across various cancer types to improve patient outcomes. Prior to this supplemental approval, Opdivo had already established its role as an important treatment option for several advanced malignancies, reflecting its broad utility in cancer care.
What this means
This supplemental FDA approval for Opdivo (nivolumab) signifies an expansion of its approved therapeutic uses based on new efficacy data. While the specific new indication or patient population is not detailed in the provided data, a supplemental efficacy approval typically means that new clinical evidence has demonstrated the drug's benefit in an additional context. This allows clinicians to prescribe nivolumab for a broader range of patients or conditions, potentially offering new treatment options where unmet needs exist. For patients, this could translate to access to an effective immunotherapy for a previously unapproved cancer type or stage, or for a different line of therapy, thereby improving their treatment landscape.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA). The approval for Opdivo (nivolumab), identified as BLA 125554 S-55, was documented on December 20, 2017, and is accessible via accessdata.fda.gov.